Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carcinoma (ccRCC; cohort A) and advanced non-ccRCC (cohort B). Results of cohort A are reported.
In this open-label, single-arm phase II study, patients with advanced ccRCC received pembrolizumab 200 mg every 3 weeks for ≤ 24 months. The primary end point was objective response rate by RECIST, version 1.1.
In the total population (N = 110), median time from enrollment to data cutoff was 35.9 (range, 29.5-40.3) months. Objective response rate was 36.4% with four (3.6%) complete responses and 36 (32.7%) partial responses; disease control rate was 58.2% (95% CI, 48.4 to 67.5). Most patients (68.2%) had a decrease in target lesions, including 30.9% with a reduction ≥ 60%. Median duration of response was 18.9 (range, 2.3-37.6+) months; 64.1% of responders had a response ≥ 12 months (Kaplan-Meier). Median progression-free survival was 7.1 months (95% CI, 5.6 to 11.0). Median overall survival was not reached; 12-month and 24-month overall survival rates were 88.2% and 70.8%, respectively. Durable responses were observed across all International Metastatic RCC Database Consortium categories. Grade 3-5 treatment-related adverse events were reported in 30.0% of patients, of which colitis and diarrhea were most frequent.
Single-agent pembrolizumab showed promising antitumor activity as a first-line treatment in patients with advanced ccRCC, with durable responses across International Metastatic RCC Database Consortium categories. Safety and tolerability profile of pembrolizumab monotherapy was comparable to what has been previously described in other tumor types.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Feb 02 [Epub ahead of print]
David F McDermott, Jae-Lyun Lee, Georg A Bjarnason, James M G Larkin, Rustem A Gafanov, Mark D Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S Tykodi, Teresa Alonso-Gordoa, Daniel C Cho, Poul F Geertsen, Miguel Angel Climent Duran, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F Perini, Charles Schloss, Michael B Atkins
Dana-Farber/Harvard Cancer Center, Boston, MA., Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea., Sunnybrook Odette Cancer Centre, Toronto, ON, Canada., Institute of Cancer Research, London, UK., Russian Scientific Center of Roentgen Radiology, Moscow, Russia., Carilion Clinic, Roanoke, VA., Odense University Hospital, Odense, Denmark., Aarhus University Hospital, Aarhus, Denmark., Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK., Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic., University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA., Hospital Universitario Ramón y Cajal, Madrid, Spain., Perlmutter Cancer Center at NYU Langone Medical Center, New York, NY., Herlev Hospital, University of Copenhagen, Herlev, Denmark., Instituto Valenciano de Oncología, València, Spain., Arizona Oncology/US Oncology, Tucson AZ., Merck & Co., Inc., Kenilworth, NJ., Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.